Commentary

Video

Supplements and Featured Publications
Reviewing Key Updates in the Realm of HER2+ and HER2-Low Breast Cancer
Volume 1
Issue 1

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer

Giuseppe Curigliano, MD, PhD, discusses findings from the phase 3 DESTINY-Breast06 trial of T-DXd in HER2-low or HER2-ultralow metastatic breast cancer.

Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology, discusses key findings from the phase 3 DESTINY-Breast06 trial (NCT04494425) investigating fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer who have received prior endocrine therapy.

DESTINY-Breast06 enrolled 866 patients who were randomly assigned to receive either T-DXd (n = 436) or investigator’s choice of chemotherapy (n = 430). At a median follow-up of 18 months, patients with HER2-low disease who received T-DXd (n = 359) achieved a statistically significant and clinically meaningful progression-free survival (PFS) benefit compared with those who received standard chemotherapy (n = 354), Curigliano says. The median PFS in the HER2-low population was 8.1 months per blinded independent central review with chemotherapy vs 13.2 months with T-DXd (HR, 0.62; 95% CI, 0.51-0.74; P < .0001). Furthermore, the median PFS in the intention-to-treat (ITT) population—comprising patients with both HER2-low or -ultralow disease—was 8.1 months with chemotherapy vs 13.2 months with T-DXd (HR, 0.63; 95% CI, 0.53-0.75; P < .0001).

A trend toward improved overall survival (OS) in the ITT population was observed with T-DXd vs chemotherapy in the landmark 1-year analysis, Curigliano notes. The 12-month OS rates were 81.1% with chemotherapy vs 87.0% with T-DXd (HR, 0.81; 95% CI, 0.65-1.00).

Efficacy outcomes with T-DXd in patients with HER2-ultralow disease were consistent with those seen with the agent in patients with HER2-low disease, Curigliano emphasizes. In the HER2-ultralow population, the median PFS was 8.3 months with chemotherapy (n = 76) vs 13.2 months with T-DXd (n = 76; HR, 0.78; 95% CI, 0.50-1.21). The 1-year OS rates were 78.7% in the chemotherapy arm vs 84.0% in the T-DXd arm (HR, 0.75; 95% CI, 0.43-1.29).

Clinical benefit with T-DXd vs chemotherapy was observed across prespecified subgroups of patients with HER2-low disease, according to Curigliano. The confirmed overall response rate with T-DXd was 57.3% in the ITT population and 61.8% in the HER2-ultralow population. In these respective populations, the clinical benefit rates with T-DXd were 76.6% and 76.3%.

No new safety signals with T-DXd have been observed, Curigliano explains. Notably, any-grade interstitial lung disease was reported in 11.3% of patients who received T-DXd, Curigliano concludes.

Related Videos
Joseph Franses, MD, PhD
Shipra Gandhi, MD
Chih-Yi Liao, MD
Mazyar Shadman, MD, MPH
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School